Literature DB >> 11840367

Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients: association with Chlamydia pneumoniae seropositivity.

Peter Stenvinkel1, Olof Heimbürger, Tomas Jogestrand.   

Abstract

The cardiovascular mortality rate is unacceptably high in patients with end-stage renal disease (ESRD), which suggests an accelerated atherogenic process. The cause(s) of the accelerated atherogenesis in ESRD patients are not known, though recent studies suggest that persistent infection, such as Chlamydia pneumoniae, and proinflammatory cytokines may contribute. Forty-five ESRD patients (26 men) aged 51 +/- 2 years was studied at a time-point close to start of dialysis treatment and again after about 12 months of dialysis treatment. By using noninvasive B-mode ultrasonography, we evaluated changes in a surrogate marker of atherosclerosis, calculated intima media (cIM) area, in the common carotid artery. C-reactive protein (CRP), S-albumin, and interleukin-6 (IL-6) assessed the presence of an inflammatory reaction. We also measured C pneumoniae antibodies by microimmunofluorescence, nutritional status by subjective global assessment, lipid parameters, smoking habits, and the presence of comorbidity close to the start of dialysis. No significant changes in the prevalence of carotid plaques or the mean cIM area were observed during the first 12 months of dialysis. However, because some patients showed marked increases in the cIM area during only 12 months of dialysis we divided the patients into 2 groups: 23 nonprogressors ((delta)cIM area -2.7 +/- 0.4 mm2) and 22 progressors ((delta)cIM area 3.6 +/- 0.7 mm2). Sex, age, body mass index, comorbidity, blood lipid levels, S-albumin, and CRP levels did not differ significantly between the 2 groups. On the other hand, progressors had a significantly elevated basal median level of IL-6 (5.7 versus 3.1 pg/mL; P < 0.05) and an increased prevalence of positive (> or 1/64) immunoglobulin (Ig) A antichlamydia antibodies (59% versus 17%; P < 0.01) compared with nonprogressors. A significant positive (R = 0.41; P < 0.01) correlation was found between Log IL-6 and changes in the cIM area during 12 months of dialysis. In a stepwise multiple regression model, Log IL-6 did predict, independently (P < 0.01) of traditional risk factors and C pneumoniae antibodies, changes in the cIM area. These data suggest that a persistent chlamydial infection stimulates IL-6 levels, which in turn may be involved in the pathogenesis of accelerated carotid atherosclerosis in dialysis patients. Copyright 2002 by the National Kidney Foundation, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11840367     DOI: 10.1053/ajkd.2002.30546

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  25 in total

1.  Impact of seropositivity to Chlamydia pneumoniae and anti-hHSP60 on cardiovascular events in hemodialysis patients.

Authors:  Pasquale Esposito; Carmine Tinelli; Carmelo Libetta; Elisa Gabanti; Teresa Rampino; Antonio Dal Canton
Journal:  Cell Stress Chaperones       Date:  2010-10-05       Impact factor: 3.667

2.  Correlative association of interleukin-6 with intima media thickness: a meta-analysis.

Authors:  Bo Zhang; Jing Wang; Yong Xu; Xiao Zhou; Junsong Liu; Jing Xu; Bo Li; Guang Zhi
Journal:  Int J Clin Exp Med       Date:  2015-03-15

3.  Correlates of resistin in children with chronic kidney disease: the chronic kidney disease in children cohort.

Authors:  Edward Nehus; Susan Furth; Bradley Warady; Mark Mitsnefes
Journal:  J Pediatr       Date:  2012-03-14       Impact factor: 4.406

4.  Anti-Inflammatory and Anti-Oxidative Nutrition in Hypoalbuminemic Dialysis Patients (AIONID) study: results of the pilot-feasibility, double-blind, randomized, placebo-controlled trial.

Authors:  Manoch Rattanasompattikul; Miklos Z Molnar; Martin L Lee; Ramanath Dukkipati; Rachelle Bross; Jennie Jing; Youngmee Kim; Anne C Voss; Debbie Benner; Usama Feroze; Iain C Macdougall; John A Tayek; Keith C Norris; Joel D Kopple; Mark Unruh; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  J Cachexia Sarcopenia Muscle       Date:  2013-09-20       Impact factor: 12.910

5.  Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease.

Authors:  Jair Munoz Mendoza; Tamara Isakova; Xuan Cai; Liz Y Bayes; Christian Faul; Julia J Scialla; James P Lash; Jing Chen; Jiang He; Sankar Navaneethan; Lavinia Negrea; Sylvia E Rosas; Matthias Kretzler; Lisa Nessel; Dawei Xie; Amanda Hyre Anderson; Dominic S Raj; Myles Wolf
Journal:  Kidney Int       Date:  2016-12-22       Impact factor: 10.612

6.  IL-6 levels, nutritional status, and mortality in prevalent hemodialysis patients.

Authors:  Ilia Beberashvili; Inna Sinuani; Ada Azar; Hila Yasur; Gregory Shapiro; Leonid Feldman; Zhan Averbukh; Joshua Weissgarten
Journal:  Clin J Am Soc Nephrol       Date:  2011-08-18       Impact factor: 8.237

7.  Accumulation of retained nonfunctional arteriovenous grafts correlates with severity of inflammation in asymptomatic ESRD patients.

Authors:  Haimanot Wasse; Francesca Cardarelli; Christine De Staercke; W Craig Hooper; Qi Long
Journal:  Nephrol Dial Transplant       Date:  2012-10-22       Impact factor: 5.992

Review 8.  Impact of medical comorbid disease on antidepressant treatment of major depressive disorder.

Authors:  Dan V Iosifescu; Bettina Bankier; Maurizio Fava
Journal:  Curr Psychiatry Rep       Date:  2004-06       Impact factor: 5.285

Review 9.  Aspects of immune dysfunction in end-stage renal disease.

Authors:  Sawako Kato; Michal Chmielewski; Hirokazu Honda; Roberto Pecoits-Filho; Seiichi Matsuo; Yukio Yuzawa; Anders Tranaeus; Peter Stenvinkel; Bengt Lindholm
Journal:  Clin J Am Soc Nephrol       Date:  2008-08-13       Impact factor: 8.237

10.  Associations of serologic markers of infection and inflammation with vascular disease events and mortality in American dialysis patients.

Authors:  Krista L Lentine; Julie Parsonnet; Isabella Taylor; Elizabeth M Wrone; Richard A Lafayette
Journal:  Clin Exp Nephrol       Date:  2006-03       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.